Intravenous atropine treatment in infantile hypertrophic pyloric stenosis

Hypertrophic pyloric stenosis of infancy is a disorder of early infancy with typical clinical features and well-established radiological appearances of the pyloric canal. Many studies with surgical and medical treatment have been reported over the past fifty years. Pylorotomy has tended to become the favoured method of treatment as with expert paediatric, surgical, anaesthetic, and nursing services and specialised accommodation for infants, the outcome is good with low mortality, short stay in hospital and few complications. However, a variety of studies of medical treatment with anticholinergic drugs and successful outcomes in some large series of cases have also been reported from Sweden, United States of America and the United Kingdom.

Since 1996 this group of workers from Osaka, Japan, has revived an interest in medical treatment with reports of a new regime using methyl atropine nitrate intravenously. To achieve satisfactory short term outcomes considerable variation in drug dosage and modified feeding regimes were necessary which involved much medical supervision and careful monitoring for toxic effects of the drug, which were minimal. The treatment was successful in the relatively small number of infants in the trial (19) with two infants being referred for pylorotomy, no mortality and no serious complications. An interesting part of this paper is the long term clinical follow up of the successfully treated infants over two years and ultrasonography of the pyloric canal which demonstrated the changes in muscle thickness and length of the canal. The disadvantages of the treatment mentioned by the authors are length of stay in hospital and the necessity to continue atropine medication orally after discharge home.

Comparing the use of this anticholinergic drug intravenously with oral treatment using methyl scopolamine nitrate and similar restricted feeding regime, oral methyl scopolamine nitrate suppressed vomiting more quickly and reliably, was also available for subcutaneous injection if vomiting recurred as size of feeds was increased, and no toxic effects were seen in any dosage used. It would be interesting if these workers would be prepared to try the use of methyl scopolamine nitrate intravenously as pharmalogically this compound was reported to have a spasmyloic effect on gut two to three times greater than methyl atropine nitrate with lesser central nervous effects.

This paper serves to emphasise once more that these infants should always be treated in paediatric centres where there is a high level of experienced paediatric care and nurses trained for neonatal special care.

B Corner
Flat 4 Chartley, The Avenue, Sneyd Park, Bristol BS9 1PE

Author’s reply

We appreciate the interest shown by Dr Beryl Corner with regard to our article.1 Unfortunatley, intravenous atropine therapy is not widely accepted in European countries or the United States; it is however now becoming popular in Japan.

We are truly honoured to receive the comments of Dr Corner, who is a pioneering neonatologist and reported medical treatment with methyl scopolamine nitrate for infantile hypertrophic pyloric stenosis (HIPS) in 1955.2 She pointed out that methyl scopolamine might be better than atropine sulphate in terms of effectiveness and side effects. One of the reasons why atropine was used in our study is that methyl scopolamine is not available in our country. Scopolamine butyrylcholine is an available quaternary ammonium derivative of scopolamine and lacks toxic side effects.

However, this agent tastes bitter and is difficult to give orally to infants. Therefore, this agent is only given intravenously in infants with HIPS.

We do not know if it is worthwhile to attempt combination therapy with intravenous scopolamine butyrylcholine and oral atropine rather than the intravenous and oral atropine therapy. Secondly, we already knew that an intravenous atropine injection of 0.01 mg/kg was effective enough to abolish transiently the phasic and tonic pyloric contractions characteristics of HIPS.3 We used an intravenous atropine injection of 0.01 mg/kg in our study to confirm that those pyloric contractions were the cause of disturbed transpyloric flow in this condition by seeing that their inhibition with the dose of atropine ameliorated symptoms.

We agree with Dr Corner’s last comment, but believe that intravenous atropine therapy is possible not only in high level paediatric centres, but also in general hospitals where infussion therapy with intravenous atropine injections can be done safely in small infants. Clinical trials are now ongoing to establish more efficient treatment strategy for HIPS with medical and surgical therapy in our country.

H Kawahara
Consultant Paediatric Surgeon, Osaka Medical Centre and Research Institute for Maternal and Child Health, kawahara@ped Surg.med.osaka-u.ac.jp

References


Hypothermia in a child secondary to ibuprofen

A 7 year old girl was admitted with right lower lobe pneumonia. On admission her temperature was 39.7°C. After five hours she received ibuprofen (6 mg/kg), subsequent to this single dose her temperature decreased to 33.5°C (core temperature 34.9°C) over four hours.

Results of investigations included: Hb 125 g/l; white blood cell count 10.7 × 10⁹/l; platelet count 81 × 10⁹/l; C reactive protein 180 mg/l; blood glucose 4.6 mmol/l. Electrolytes and all other biochemical investigations were normal. Thyroid and cortisol assays were normal. Results of all tests to determine possible bacterial or viral aetiology were all negative (blood and urine culture, viral serology, and tests for mycoplasma). Magnetic resonance imaging (MRI) of the brain was normal.

The hypothermia was so marked that we had to use a hot air spacer blanket to raise her temperature. Despite all the efforts she remained persistently hypothermic for four days (see fig 1).

Figure 1 Temperature chart. After administration of ibuprofen, the temperature dropped considerably and remained low for five days.
A single dose of hydrocortisone and an albumin infusion were given initially. She was subsequently treated with warmed intravenous fluids for three days and antibiotics for 10 days. She recovered completely and continues to enjoy good health.

Vagal overactivity is extremely rare in children over 5 years of age. Results of investigations excluded infective and endocrine causes. A normal MRI brain scan showed no lesion of the hypothalamus or corpus callosum.

Ibuprofen is commonly prescribed for a raised temperature and is well tolerated in children. Side effects are not common, even in overdose. Nonetheless we postulate that ibuprofen was responsible for hypothermia in this case. We are not aware of any published evidence documenting hypothermia after a single therapeutic dose of ibuprofen, but it has been recorded in a few cases of accidental and deliberate overdose. Although patients may sometimes receive ibuprofen in toxic quantities, hypothermia is not a consistent feature. Hypothermia in overdose is attributed to central nervous system depression.1

R P Desai
Southend Hospital, Room 2, Doctor’s Quarters, Chelmsford Accommodation, St John’s Hospital, Chelmsford CM2 9BG, UK; prpravin@yahoo.com

S Sriskandan
Department of Paediatrics, Southend Hospital, Priitwell Chase, Southend on Sea SS0 0RY, UK

References

Vagal overactivity: a risk factor of sudden infant death syndrome?

Since early 1990, the incidence of sudden infant death syndrome (SIDS) has dropped sharply because of public health campaigns decrying the dangers of the prone sleep position. The other known risk factors, such as preterm birth and young maternal age, are less susceptible to campaign efforts.

Disordered autonomic function, including cardiorespiratory control, has been suggested to be involved in SIDS.2 Vagal overactivity (VO), characterised by breath holding spells and repeated syncope in specific circumstances, has been described as a manifestation of autonomic dysfunction.4 To investigate a possible relation between VO and SIDS, we investigated 65 children presenting documented VO; for example, clinical characteristics and a positive test for eyeball compression and/or electrocardiographic monitoring. Parents of these children were interviewed about their family history, especially with respect to the occurrence of SIDS among their own children.

Among their siblings, five of 126 had died of SIDS. All five children were full term infants. The average maternal age, birth weight, and age at death were respectively 27.4 (3.5) years, 3.3 (0.3) kg, and 3.5 (1.1) months. The rates of SIDS in siblings of children with VO were compared to the in the general population using the standardised incidence ratio (SIR), which is the ratio of the observed number to the expected number of cases of SIDS calculated from general birth rates. The expected number of SIDS was 0.17 and hence the SIR was 29.4 (95% CI 9.5 to 68.6; p < 0.00001). Our result showed an overall significant excess of SIDS among siblings of children with VO. However, the VO children had not come to the centre because of a family history of SIDS. Since children with a positive family history of SIDS could be followed up more regularly than others, we estimated the SIR separately among siblings of children recruited during their follow up and those of children recruited during their first visit, and verified that there was no significant difference in SIR between these cases. Despite the marked decline in SIDS, it is still the leading cause of postneonatal mortality. Better knowledge of other risk factors may allow identification of populations at high risk and a decrease in infant mortality from SIDS through the implementation of appropriate prevention measures. Our findings suggest that VO may be involved in SIDS and that children with VO or a family history of VO may be a population at potential high risk of SIDS.

T Shojaei-Brosseau, C Bonaiti-Pellie
Unité de Recherche en Épidémiologie des Cancers, INSERM U521, Villejuif, France

S Lyonnct, J Feingold
Unité de recherche sur les Handicaps Génétiques de l’Enfant, INSERM, US939, Paris, France

V Lucet
Centre de Cardiologie Infantile du Château des Côtes, Les Loges-en-Josas, France

Correspondence to: Dr T Shojaei-Brosseau, Service de Biostatistiques, Institut Curie, 70 rue Mouffetard, 75005 Paris, France; tshoanesh.shoajie@curie.net

Perforated duodenal ulcer disclosing medium chain acyl-CoA dehydrogenase deficiency

Medium chain acyl-CoA dehydrogenase deficiency (MCADD; McKusick 21430) typically presents in the first two years of life with recurrent episodes of hypoketotic hypoglycaemia, lethargy, coma, or sudden infant death. The trigger may be fasting, infectious intercurrent illness, anaesthesia, or surgery. Incidence in the UK is estimated at 0.45–1/10 000 live births.1 We describe the case of a child who presented with marked encephalopathy unexplained by perforated duodenal ulcer, which led to the diagnosis of MCADD.

A 10 year old girl presented with a three week history of corval symptoms and three day history of frequent coffee ground vomiting. She was shocked, and had hepatomegaly and decreased conscious level. Blood glucose was 3.9 mmol/l (reference interval 3.3–5.3), plasma sodium 129 mmol/l (135–147), potassium 5.2 mmol/l (3.5–5.0), urea 17.8 mmol/l (3.3–6.6), creatinine 36 mmol/l (30–74), bicarbonate 15 mmol/l (21–28), sodium 135 mmol/l (134–144), and C reactive protein 4 mg/l (0–5). Liver function tests and clotting were normal. She was resuscitated with a total of 50 ml/kg of colloidal and crystalloid. The following day she relapsed with abdominal distension, shock, and deteriorating conscious level. Investigations showed glucose 14.2 mmol/l, amylase 20 IU/l (8–85), AST 186 IU/l (10–45), and ALT 129 IU/l (10–40). An x-ray examination of the abdomen showed free air under the right hemidiaphragm. Emergency laparotomy revealed a single, 1 cm x 1 cm acute perforation in the second part of the duodenum. Histology and rapid urease test (CL0) of the duodenal biopsy for Helicobacter pylori were negative. Fasting blood gastrin was 20 mU/l (10–100). She was discharged home taking omeprazole. Upper gastrointestinal endoscopic biopsy (eight weeks later) for histopathology and CLO test from oesophagus, stomach, antrum, and duodenum were normal.

Analysis of urinary organic acids by gas chromatography and mass spectrometry, obtained a day after clinical presentation, revealed a marked increase in 5-hydroxyhexanoic acid (21% of total organic acids); a modest dicarboxylic aciduria (sulbic acid accounted for 8% and adipic 6% of total organic acids); and a small but significant quantity of hexanoylglycerin (2% of total organic acids) in the absence of ketonuria.

Blood obtained a week after clinical presentation, when analysed by tandem mass spectrometry, showed octanoylglycerin 0.15 mmol/l (<0.19), hexanoylglycerin 0.67 mmol/l (<0.29), and deconooylarginine 0.63 mmol/l (<0.10), with a subnormal concentration of acetylcarnitine 4.0 mmol/l (6.2–27.5). This profile was consistent with MCADD. Polymerase chain reaction/restriction digests based method revealed two mutations in the MCAD gene.

The clinical details coupled with the absence of ketones and the increased 5-hydroxyhexanoic acid led us to look for an abnormality in the oxidation of fatty acids, and resulted in identification of the minor constituent, hexanoylglycerin that is recognised as an indicative marker of MCADD. Increases in urinary hexanoylglycerin and 5-hydroxyhexanoic acids in the absence of ketonuria have been reported previously in MCADD patients during clinical attack,1 and also in a boy who died.1 Our case was unusual in that the amount of 5-hydroxyhexanoic acid was greater than even the sum of the individual dicarboxylic acids present, although high levels of 5-hydroxyhexanoic acids are reported in acute episodes.1 The increased concentration of octanoyl carnitine in blood was also consistent with a diagnosis of MCADD.

We believe that this is the first report of MCADD presenting with duodenal ulcer. It could be argued that the ulcer was the primary problem and that the decompen- sation was caused by the subsequent illness.
Thus, any child who has unexplained encephalopathy, regardless of its cause and clinical setting, should be screened for MCADD.

V Kairamkonda, M Dalzell
Department of Gastroenterology, Royal Liverpool Children’s NHS Trust, Alder Hey Children’s Hospital, Liverpool, UK

P D Losty
Department of Surgery, Royal Liverpool Children’s NHS Trust, Alder Hey Children’s Hospital

C Davidson
Department of Metabolic Medicine, Royal Liverpool Children’s NHS Trust, Alder Hey Children’s Hospital

Correspondence to: Dr M Dalzell, Department of Gastroenterology, Royal Liverpool Children’s NHS Trust, Alder Hey Children’s Hospital, Liverpool L12 2AP, UK, mark.dalzell@lch.tr.nhs.uk

References


Glucose metabolism in sleep disordered breathing

An association between sleep disordered breathing (SDB) and impaired glucose tolerance has been reported in adults.1 Although SDB has been reported in diabetic children, no data are available on glucose metabolism in children with SDB. We used glycated haemoglobin (HbA1c) for the preliminary assessment of glucose metabolism in paediatric SDB patients.

HbA1c was measured in 12 children aged 26–116 months (mean 63) with suspected SDB owing to adenotonsillar hypertrophy. Informed consent was obtained from the guardians of each patient, and consent was obtained from the child if older than 5 years of age. Overnight polysomnographic studies were performed once for each patient by the standard method described elsewhere. The desaturation time (percentage of total sleep time with oxygen saturation <90%), minimum oxygen saturation level, and apnoeas-hypopnoeas index (AHI) were calculated. Complete blood count, blood gases, and blood chemistry (glucose, total protein, albumin, urca nitrogen, creatinine, uric acid, sodium, chloride, potassium, calcium, phosphate, lactate dehydrogenase, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, γ-glutamyl transpeptidase, alkaline phosphatase, total bilirubin, total cholesterol, and triglycerides) were also determined.

The patients had no respiratory failure, heart failure, or coma. None of their weights exceeded 120% of their ideal weight for their heights. Desaturation time clearly divided the patients into two groups: six patients whose desaturation time was 0 or 0.1 (mild SDB group); and six whose desaturation time exceeded 4.0 (severe SDB group). The average HbA1c value for the severe SDB group (5.0, SE 0.07) was significantly higher than that for the mild SDB group (4.6, SE 0.10) (p = 0.01), although the actual HbA1c values were all within normal range. No other items showed significant differences between the two groups.

The severity of respiratory disturbances during sleep in diabetic children has been known to correlate with the duration of diabetes and with the HbA1c value.1 Recently, SDB parameters were found to be associated with worsening insulin resistance independent of obesity in adults.2 The current study shows that serum HbA1c is increased in association with the degree of desaturation in non-obese paediatric SDB patients; HbA1c levels should, however, be monitored after treatment. SDB and glucose metabolism are hypothesised to be closely associated in children as well as adults.

J Kohyama, T Hasegawa, J S Ohinata
Department of Pediatrics, Faculty of Medicine, Tokyo Medical and Dental University, Japan

Correspondence to: Dr J Kohyama, Department of Pediatrics, Faculty of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Tokyo 113-8519, Japan; kohyama33@md.ac.jp

References


Short versus standard duration antibiotic treatment for UTIs: a comparison of two meta-analyses

Having recently published a meta-analysis on the same clinical question,1 it was with great interest that we read Michael et al’s systematic review of short versus standard duration antibiotic treatment for urinary tract infections (UTIs) in children.2 Given the publication (in close succession) of two meta-analyses on the same question with (on the surface) strikingly different results, we thought a comment was in order.

First, we applaud the authors on their methodologically sound review. The literature search was explicitly described and exhaustive. In fact, the authors identified a few studies that we had missed.3 The study outcomes for meta-analysis (frequency of positive urine cultures at 0–7 days after treatment and at 10 days to 15 months after treatment, and development of resistant organisms and recurrent UTI) were relevant and clearly defined.

The authors provided appropriate and important meta-analysis measures including summary relative risks (RRs) and a quasi-NNT calculation with varying risk of treatment failure in the standard treatment group and confidence intervals corresponding to “best” and “worst” case scenarios. For their primary outcome, frequency of positive urine cultures 0–7 days after treatment, the authors found no significant difference between short (3–5 days) and standard (7–14 days) treatment (RR 1.06; 95% CI 0.64 to 1.76). This is in contrast to our finding of a 94% increased pooled risk of treatment failure with short course treatment (RR < 3 days) compared to standard treatment (7–14 days) (RR 1.94, 95% CI 1.19 to 3.15; NNT=13, 95% CI 100 to 7). Why the discrepancy? We postulate a few possible explanations and conclude that the two meta-analyses, on closer inspection, actually have very similar results.

Our omission of certain studies identified by Michael and colleagues may have biased our results. However, of the three studies3 that we missed and that they included in their analysis of treatment failure at 0–7 days after completion of treatment, two favoured standard duration treatment, which would have supported our pooled RR result. Another possible explanation for the divergent results was the use of different definitions of treatment failure. For our definition of treatment failure we pooled persistent infection (failure to eradicate the organism within 2 weeks of initiation of treatment) and relapse (recurrence of symptoms and reinfection within 2 weeks of cessation of treatment after initial bacteriologic cure), whereas Michael et al used frequency of positive cultures 0–7 days after cessation of treatment as their primary outcome measure of treatment failure. If reinfections later than 7 days after cessation of treatment occurred more often in recipients of short-course treatment, then Michael et al’s definition of treatment failure could have failed to capture the therapeutic advantage of standard duration treatment.

However, the most likely explanation for the divergent results was the different ways in which the study question was framed and the resulting differences in studies included in the meta-analyses. We compared ≤3 days of treatment to 7–14 days of treatment, whereas Michael et al compared 2–4 days of treatment to 7–14 days of treatment and excluded 11 studies comparing single-dose or single-day treatment to standard duration treatment.4,5,6

The reasons for this exclusion are unclear, although we assume that they felt single-dose or single-day treatment was not a fair comparison with 7–14 day treatment. However, a number of randomised controlled trials (RCTs) made this comparison, suggesting that clinicians are, in fact, interested in the potential efficacy and (significantly increased cost) of single-dose or single-day treatment. Inclusion of these studies in our analysis strongly influenced the pooled risk of treatment failure for short-course treatment vs standard (1.94; 95% CI 1.19 to 3.15). When we excluded these studies in a sub-group analysis of 3-day versus long course (7–14 day) treatment, the risk of treatment failure fell to 1.36 (95% CI 0.68 to 2.72) (NNT=50; 95% CI 33 - 13).

Thus, our meta-analysis demonstrates clearly that single dose or single day antibiotic treatment is not as effective as long-course treatment for UTIs in children. The two meta-analyses together suggest that: (1) “longer” short-course therapies may be as effective as 7–14 days of antibiotics and...
(2) there is probably a duration of treatment threshold for “short-course” antibiotic treatment, above which longer duration of treatment confers no therapeutic advantage.

Michael and colleagues suggest that as little as 2 days of treatment may be sufficient. However, only one of the trials in their meta-analysis studied 2-day treatment and that only compared short-course treatment with a RR of UTI 0–7 days after completing short course treatment of 2.17 (95% CI 0.48 to 9.76). The duration of treatment threshold may be 3 days, but the point estimate of relative risk of treatment failure with 3 day treatment in their meta-analysis suggests otherwise. If the duration of short-course treatment for which there is no difference in efficacy compared with standard duration antibiotic treatment is actually greater than 3 days, then the added convenience and cost-savings of “short-course” treatment become marginal. In the absence of appropriately powered RCTs (or meta-analyses) examining outcomes (treatment failure, reinfection, emergence of resistant organisms and cost) with “longer” short course treatment regimens (3, 4, and 5 days), we think that clinicians should continue to treat UTIs in children with at least 7 days of antibiotics.

R Keren
Department of Pediatrics, The Children’s Hospital of Philadelphia, USA
E Chan
Department of Pediatrics, The Children’s Hospital of Boston, USA

Correspondence to: R Keren; keren@email.chop.edu

References

Authors’ reply
In response to Keren and Chan’s thoughtful letter regarding our recent systematic review, we need to emphasise that the study question we addressed was different from that addressed by Keren and Chan in their own systematic review of randomised controlled trials comparing short with standard duration treatment in the treatment of children with urinary tract infections (UTI). The aim of our study was to determine the relative efficacies of short (2–4 days) and standard duration (7–14 days) treatment. In their letter above, Keren and Chan argue that this study favours standard duration treatment. However, there was no significant difference between treatments in the number of children with persistent bacteriuria at the end of treatment (RR 2.17; 95% CI 0.48 to 9.76) although the wide confidence intervals do not exclude the possibility that short duration treatment could be more or less effective than standard duration treatment.

No significant differences in the number of children with persistent UTI after treatment between short duration and standard duration antibiotic treatment have been found in three systematic reviews of randomised controlled trials despite different study inclusion criteria and definitions of persistent infection. As addressed in our review, the wide confidence intervals around the summary estimates indicate residual imprecision in the results. However, this statistical imprecision is of doubtful significance for most children, who are at a low risk (1–3%) of persistent UTI at the end of treatment following their first lower tract UTI. Therefore, we do not support Keren and Chan’s conclusion that clinicians should continue to use short-course UTI with standard duration treatment. Instead, we believe that short duration treatment may be used to treat children with lower tract UTI.

E M Hudson, M Michael, J C Craig, V A Moyer
Centre for Kiddies Research, The Children’s Hospital at Westmead, Sydney, Australia

Correspondence to: E Hudson; Elissah@chw.edu.au

References

Table 1 Results of three systematic reviews of randomised controlled trials comparing short duration with standard duration of antibiotic treatment for lower tract urinary tract infection.

<table>
<thead>
<tr>
<th>Systematic review</th>
<th>Comparison of duration of therapy</th>
<th>Number of data sets</th>
<th>Risk for persistent bacteriuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tran et al. 2001</td>
<td>1–4 days v &gt;5 days</td>
<td>13</td>
<td>RD: 4.26 (95% CI: 0.95, 9.48)</td>
</tr>
<tr>
<td>Keren &amp; Chan, 2002</td>
<td>3 days v 7–14 days</td>
<td>5</td>
<td>RR: 1.36 (95% CI: 0.68, 2.72)</td>
</tr>
<tr>
<td>Michael et al. 2002</td>
<td>2–4 days v 7–14 days</td>
<td>8</td>
<td>RR: 1.06 (95% CI: 0.64, 1.76)</td>
</tr>
</tbody>
</table>

*RD*, risk difference; *CI*, confidence intervals; *RR*, relative risk
Is life long follow up for patients with Kawasaki disease indicated?

Brogan et al recommended life long follow up for patients with Kawasaki disease, including those who do not have coronary artery involvement. The reason they quoted was to document the blood pressure and provide general advice regarding other risk factors. The American Heart Association recommends echocardiographic (EGC) evaluation of the coronary arteries at presentation and follow up ECG at 6–8 weeks and 6–12 months after the onset of symptoms for those who did not have or just have transient coronary artery involvement. They do not recommend follow up after first year unless cardiac disease is suspected. Tuohy et al demonstrated, in their multi-institutional review of 536 patients, that no patient with a normal follow up ECG, performed within 2 months following disease onset, subsequently developed echocardiographic coronary artery abnormalities. Even those patients with initial echocardiographic abnormalities that became normal at 1–2 months remained normal thereafter. Scott and colleagues showed that no patient with a normal ECG at 2 weeks to 2 months after the onset of symptoms had subsequent ECGs that revealed coronary artery abnormalities. They questioned the value of 6–12 month ECG in the same group.

Brogan et al did not make any comments about the adverse effects of life long follow up, such as anxiety and inappropriate restriction of activities. Finally, there were no comments about the cost and resources for providing life long follow up. The authors did not specify which paediatric cardiologists, general paediatricians, or general practitioners would follow up; all of them already have increasing demands of workload.

References


Management of childhood osteoporosis

I read with interest this recent review article that summarises current knowledge about this subject. I have a number of comments that are pertinent to the discussion. As the authors allude to, there is currently a lack of good evidence on which we can base preventive management. Although calcium and vitamin D supplements are routinely used by some paediatric rheumatologists, there appears to be only one short term study suggesting this may be beneficial for bone density. The reason they quoted was to show the importance of good evidence in relation to growth hormone therapy are methodologically flawed because neither have accounted for the change in apparent bone density, which will occur in any child who grows better for any reason when assessed by modalities such as dual energy x ray absorptiom-etry.

As illustrated by another article in the August 2002 edition of Archives, there is a lack of good evidence on which to base much paediatric management and it is imperative that further research, especially randomised controlled trials, is undertaken in the area of prophylaxis to prevent osteoporosis in children with chronic disease on steroids. Paediatric endocrinologists will be familiar with the flurry of small uncontrolled studies undertaken in numerous groups of children with chronic disease or a metabolic bone disease, when recombinant growth hormone became available. Many reports of short term improvements in growth velocity have not been supported by long term outcomes in height. There is a risk that a similar phenomenon will occur with the use of bisphosphonates in children with chronic disease and low bone density without properly designed studies and satisfactory outcome measures.

The use of glucocorticoids in children with chronic disease or a metabolic bone disease subspecialty and I would argue strongly that the management and prevention of osteoporosis requires specialist expertise just as the management of growth retardation currently does. It is important that in each tertiary centre such a specialist service is provided by one department that has expertise in the interpretation of bone density scans in children and the management of children with osteoporosis. Such individuals may not only be paediatric endocrinologists but may be a paediatric rheumatologist, a general paediatrician with a special interest in bone disease or a metabolic bone disease specialist. It is only in this way that we can learn more about the management of this condition and avoid children being treated inappropriately.

Newborn screening for Duchenne muscular dystrophy

Elliman, Deizateux, and Bedford, in their recent leading article on newborn and childhood screening, include reference to newborn screening for Duchenne muscular dystrophy (DMD), which are stripped of information and supported by their evidence with reference to the article of Jarvinen et al. While this paper does not report a newborn screening study but the results of a retrospective study of 23 females in Fineland carrier tested for DMD during childhood, however, a newborn screening programme for DMD has been running in Wales since 1990 (1990–8 as a research programme) and 1998 health authority-funded. During the research period interim evidence was published. More recently the full results of our prospective study have been published. Our evaluation has demonstrated that a newborn screening programme for DMD can be acceptable to both parents and health professionals, providing that a rigorous delivery protocol is in place and the programme is supported by an effective infrastructure, in particular by paediatric and genetic services.
Sanctions were imposed on the people of Iraq in 1990. Iraqi people are still suffering, especially children. Infant mortality (IM) has increased more than five times. Previously it had decreased from 139 in 1960 to 20 in 1989, which was comparable to developed countries. In 1992 it went up to 111. In 1999, a decade later, IM was still high at 104. The Gulf War and trade sanctions caused a three-fold increase in mortality among Iraqi children under 3 years of age. It has been estimated that more than 46,900 children died between January and August 1991. The rate of low birth weight (<2500 grams) in 1992 was 28% for stunting, 29% for underweight, and 12% for wasting. More than 10% of children were underweight (≤SD) and among children, 10% for stunting, 7% for underweight, and 3% for wasting. The survey by FAO in the year 2000 indicated the prevalence of wasting in children under 5 years of age. It has been noted among children, 10% for stunting, 12% for wasting. Severe malnutrition (≥2SD) was noted among children, 10% for stunting, 7% for underweight, and 3% for wasting. The survey by FAO in the year 2000 indicated the prevalence of wasting in children under 5 years of age. It has been noted among children, 10% for stunting, 12% for wasting. Severe malnutrition (≥2SD) was noted among children, 10% for stunting, 7% for underweight, and 3% for wasting.

The study of the UN Food and Agricultural Organisation, published in a letter to the BMJ in 1995, concluded that deaths of more than 550,000 children could be attributed to UN sanctions. It also stated that the death rate among children under 5 years in Baghdad had increased fivefold since the war ended in 1991. Data for 1994-99 showed that mortality among children under 5 years was 131 per 1000 live births, compared with 56 for 1984-9. The effect of sanctions on child mortality for children under 5 years was 131 per 1000 live births, compared with 56 for 1984-9, and the excess mortality for children under 5 years in Baghdad had increased fivefold since the war ended in 1991. There was a threefold increase in leukaemia in the southern provinces, sites of the Gulf War battlefield. A WHO investigation in 1995 suggested a possible link to products—now banned—used by the Iraqi government, which were derived from depleted uranium used in piercing artillery shells. There were staggering deficiencies in cancer treatment facilities because of UN sanctions which were intended to exclude food and medicine for children. Infant mortality (IM) in 1999 was 104. A report in 1996 showed that three times of hospital beds were closed. More than half of all diagnostic and therapeutic equipment was not working due to lack of spare parts and maintenance. All public hospitals had experienced serious problems with lighting, cleaning, water supply, and sewage. The population had been burdened by a rapid rise in serious infections, nutritional deficiencies among children and pregnant women, and other treatable conditions for which neither drugs nor operations were available.

Paediatricians have been isolated from the international medical community. Physicians who wish to attend international conferences face travel restrictions, like denial of visas to European countries or the USA. In 1990, the delivery of vaccines and other medical journals were abruptly stopped. This intellectual embargo served to undermine the care of patients, and denies Iraqi doctors the right to share scientific advancement and its benefits.

The National Immunization Programme, which had begun in 1985 came to a complete halt between January and April 1991. The percentage of fully immunised one year old children fell from 94 for tuberculosis, 83 for diphtheria, tetanus, and pertussis, 83 for polio, and 82 for measles to 79, 63, 64, and 68 respectively. A child psychology study (1991) revealed a level of psychological stress and pathological behaviour that was the highest the authors had seen in 10 years of conflict research. It revealed a highly disturbed population of children. Fear and anxiety were associated with memories of crisis. Seventy five per cent felt sad and unhappy, and four out of five expressed fear of losing their family by death or separation.

The rate of low birth weight (<2500 grams) was 25% in the age group of 0-5 years at the unacceptably high level of 10%, in these patients. A possible genetic screening for cause gene causing FMF, HIDS, or immunological assay for HLA B27 was also useful.

Correspondence to Dr Al-Nouri; al-nouri@uruklink.net

References

4 Court C. Iraq sanctions lead to half a million child mortality. BMJ 1995;311:1523.
9 Sikora C. Care of services are suffering in Iraq. BMJ 1992;318:203.


Mechanisms of pulmonary hypertension in Bardet-Biedl pertussis

Casano et al describe a case of refractory pulmonary hypertension with severe Bardet-Biedl pertussis infection. Their description of the literature is incomplete. While most cases of fatal pulmonary hypertension (PHT) in a series of 13 critically ill infants with B pertussis, the cases that developed PHT all presented with severe hyperleukocytosis (WCC>100 x 10^9/l), which was unresponsive to all currently available modalities including extra-corporeal membrane oxygenation. Hyperleukocytosis was an independent predictor of mortality. In addition however, the clinical presentation and management of these cases was such that extreme leukocytosis predisposes to the formation of lymphocyte aggregates in the pulmonary vasculature and increased pulmonary vascular resistance via obstruction rather than
hypoxic vasoconstriction. Therefore Dr Casano's recommendation for the early use of pulmonary vasodilators is unlikely to be sufficient in this context. We are assessing the impact of strategies aimed at reducing lymphocyte numbers and adhesion in addition to standard treatments for pulmonary hypertension.

M J Peters, C M Pierce
Paediatric Intensive Care Unit, Great Ormond Street Hospital, London, UK

N J Klein
Infectious Diseases and Microbiology Unit, Institute of Child Health, London, UK

Correspondence to: Dr Peters; m.peters@ich.ucl.ac.uk

References

Authors' reply
As Peters comments in his letter, we know that hyperleukocytosis has been postulated as a factor for pulmonary hypertension in Pertussis infection, but necessary brevity did not make it possible to report. Nevertheless, our patient never reached these values of leukocytosis; it's possible, as in many other diseases, that several pathogenic mechanisms contribute to pulmonary hypertension, making a concomitant treatment approach necessary.

M Pons, P Casano
Hospital Sant Joan de Déu, Unidad de Cuidados Intensivos Pediátricos, Passeig de Sant Joan de Déu, 2 080950, Esplugues de Llobregat, Barcelona, Spain

Correspondence to: Dr Pons; mpons@hsjdbcn.org

CORRECTIONS
In the paper by Clarkson and Choonara in the December issue of ADC (Arch Dis Child 2002;87:462–7) the following corrections have been noted:

Results; first sentence: there were 331 deaths with 390 suspected drugs (not 390 and 389 respectively as stated in the paper).

Results; section “Corticosteroids”: the third sentence starting “No details were avail-

able...” should be deleted.

Results; section “Non-steroidal anti-

inflammatory drugs (NSAIDs)”: the second sentence “All reports for NSAIDs have oc-

curred since 1990” should be deleted.

Discussion; fifth paragraph: the penulti-

mate sentence should be “as recently as 1999 our study found a single fatality” (not 2 reported fatalities).

Discussion; fourth paragraph, second sentence. The word “seven” before “cases” should be deleted.

The journal apologises for the errors.

The following figure should have appeared with the letter by Desai and Babu in the October issue of ADC (Arch Dis Child 2002;87:357).

Figure 1 Scimitar syndrome. Chest x ray showing a curvilinear density which extends from the right hilum towards the right hemi-diaphragm which represents the anomalous pulmonary vein.
Glucose metabolism in sleep disordered breathing

J Kohyama, T Hasegawa and J S Ohinata

Arch Dis Child 2003 88: 89
doi: 10.1136/adc.88.1.89

Updated information and services can be found at:
http://adc.bmj.com/content/88/1/89.1

These include:

References
This article cites 4 articles, 2 of which you can access for free at:
http://adc.bmj.com/content/88/1/89.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/